A formyl peptide receptor agonist suppresses inflammation and bone damage in arthritis

Abstract

Background and PurposeAnnexin A1 (AnxA1) is an endogenous anti‐inflammatory protein and agonist of the formyl peptide receptor 2 (FPR2). However, the potential for therapeutic FPR ligands to modify immune‐mediated disease has been little explored. We investigated the effects of a synthetic FPR agonist on joint disease in the K/BxN model of rheumatoid arthritis (RA) and RA fibroblast‐like synoviocytes (FLS).Experimental ApproachArthritis was induced by injection of K/BxN serum at day 0 and 2 in wild‐type (WT) or AnxA1−/− mice and clinical and histopathological manifestations measured 8–11 days later. WT mice were given the FPR agonist compound 43 (Cpd43) (6 or 30 mg·kg−1 i.p.) for 4 days. Effects of AnxA1 and Cpd43 on RANKL‐induced osteoclastogenesis were assessed in RAW 264.7 cells and human RA FLS and macrophages.Key ResultsTreatment with Cpd43 before or after the onset of arthritis reduced clinical disease severity and attenuated synovial TNF‐α and osteoclast‐associated gene expression. Deletion of AnxA1 in mice exacerbated arthritis severity in the K/BxN model. In vitro, Cpd43 suppressed osteoclastogenesis and NFAT activity elicited by RANKL, and inhibited IL‐6 secretion by mouse macrophages. In human RA joint‐derived FLS and monocyte‐derived macrophages, Cpd43 treatment inhibited IL‐6 release, while blocking FPR2 or silencing AnxA1 increased this release.Conclusions and ImplicationsThe FPR agonist Cpd43 reduced osteoclastogenesis and inflammation in a mouse model of RA and exhibited anti‐inflammatory effects in relevant human cells. These data suggest that FPR ligands may represent novel therapeutic agents capable of ameliorating inflammation and bone damage in RA.

Garcinia Multiflora Inhibits FPR1-Mediated Neutrophil Activation and Protects Against Acute Lung Injury

“…FPRs, particularly FPR1, are responsible for recognizing different endogenous or exogenous molecular stimuli in neutrophils and play a critical role in mediating neutrophil activation. A growing body of evidence supports claims that FPR1 antagonists have promising anti-inflammatory effects [28,29]. In the present study, we demonstrate that a natural constituent extracted from G. multiflora Champ.…”

FPR2/ALXR Agonists and the Resolution of Inflammation

“…In addition to these data, it was demonstrated that compound 6 also exhibited anti-inflammatory effects in relevant humans cells, suggesting that FPR ligands may represent novel therapeutic agents with which to ameliorate inflammation and bone damage in RA. 220 5.4. Inflammatory Bowel Disease (IBD).…”

Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation

“…The above agonists were characterized for their ability to induce intracellular Ca 2+ release. Whereas agonists 3 and 4 exhibited anti-inflammatory properties in peripheral models of inflammation [35,36], there are no reports on the effects of FPR2 agonists in in vitro or in vivo models of neuroinflammation.…”